gms | German Medical Science

26th Annual Meeting of the German Retina Society

German Retina Society

27.09.2013, Hamburg

Article

Send article

Everolimus reduces the metastatic potential of human uveal melanoma cells

Meeting Abstract

Search Medline for

  • Julia Lüke - Lübeck, Germany
  • D. Wildner - Lübeck, Germany
  • M. Lüke - Lübeck, Germany
  • S. Grisanti - Lübeck, Germany
  • A. Tura - Lübeck, Germany

Retinologische Gesellschaft. 26. Jahrestagung der Retinologischen Gesellschaft. Hamburg, 27.-27.09.2013. Düsseldorf: German Medical Science GMS Publishing House; 2013. Doc13rg28

doi: 10.3205/13rg28, urn:nbn:de:0183-13rg283

Published: August 20, 2013

© 2013 Lüke et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

Aim: Evaluation of the effect of Everolimus on the viability, proliferation, and migration of the uveal melanoma cell line 92.1 as well as the expression of several metastatic proteins.

Methods: The 92.1 uveal melanoma cells were cultured in RPMI1640 supplemented with 10% serum and treated with Everolimus alone or combined with Rho-Kinase inhibitor H1152. Viability and proliferation were assessed by immunostaining (Ki-67, Vimentin, beta-Catenin) und des MTT-Assays. Migration was analyzed by the scratch assay on the confluent monolayers of cells grown in 6-well plates.

Results: The MTT-tests revealed a dosage-dependent decrease of proliferation of 92.1 cells after the treatment with Everolimus especially with a concentration of 100 nM. The expression of Ki-67, Vimentin and beta-Catenin as well as the cell migration into the wound area were reduced after the treatment with Everolimus.

Conclusions: Everolimus (0.1–1 μM) induces a reduction of cell survival, proliferation and migration of human uveal melanoma cells.